Table 2 The observed and predicted 5-year OS of the MRI-based radiomics signature and NRI-M in patients with all-stages and early-stage ENKTCL.
Risk group | No. (%) | Observed 5-year OS (%) | P | Â | Predicted 5-year OS (%) |
|---|---|---|---|---|---|
All Stages (n = 176) |  |  |  |  |  |
MRI radiomics signature | Â | Â | 0.002 | Â | Â |
Type I (Favorable) | 65 (36.9) | 87.2 | Â | Â | 87.8 |
Type II (Unfavorable) | 111 (63.1) | 67.3 | Â | Â | 66.7 |
NRI-M |  |  | < 0.001 |  |  |
Low-risk (0–1) | 53 (30.1) | 90.5 |  |  | 90.9 |
Intermediate-low-risk (2) | 37 (21.0) | 80.8 | Â | Â | 83.5 |
Intermediate-high-risk (3) | 47 (26.7) | 69.6 | Â | Â | 70.9 |
High-risk (4) | 28 (15.9) | 63.4 | Â | Â | 52.0 |
Very high-risk (≥ 5) | 11 (6.3) | 22.7 |  |  | 28.8 |
Stage I–II (n = 166) |  |  |  |  |  |
MRI radiomics signature | Â | Â | 0.004 | Â | Â |
Type I (Favorable) | 63 (38.0) | 88.8 | Â | Â | 88.9 |
Type II (Unfavorable) | 103 (62.0) | 69.2 | Â | Â | 69.0 |
NRI-M |  |  | < 0.001 |  |  |
Low-risk (0–1) | 53 (31.9) | 90.5 |  |  | 90.4 |
Intermediate-low-risk (2) | 37 (22.3) | 80.8 | Â | Â | 82.9 |
Intermediate-high-risk (3) | 45 (27.1) | 71.5 | Â | Â | 70.8 |
High-risk (≥ 4) | 31 (18.7) | 54.8 |  |  | 52.8 |